1. Home
  2. NXGL vs SHPH Comparison

NXGL vs SHPH Comparison

Compare NXGL & SHPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo NexGel Inc

NXGL

NexGel Inc

N/A

Current Price

$3.94

Market Cap

2.0M

Sector

Health Care

ML Signal

N/A

Logo Shuttle Pharmaceuticals Holdings Inc.

SHPH

Shuttle Pharmaceuticals Holdings Inc.

N/A

Current Price

$5.43

Market Cap

2.1M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
NXGL
SHPH
Founded
1997
2012
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.0M
2.1M
IPO Year
2019
2022

Fundamental Metrics

Financial Performance
Metric
NXGL
SHPH
Price
$3.94
$5.43
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
★ 595.0K
37.6K
Earning Date
11-10-2026
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 24.00
N/A
EPS
★ N/A
N/A
Revenue
★ $11,421,000.00
N/A
Revenue This Year
$38.23
N/A
Revenue Next Year
$53.72
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
★ 31.46
N/A
52 Week Low
$0.15
$0.38
52 Week High
$214.40
$8.88

Technical Indicators

Market Signals
Indicator
NXGL
SHPH
Relative Strength Index (RSI) 41.19 61.63
Support Level $3.12 $2.92
Resistance Level $7.25 $5.95
Average True Range (ATR) 0.92 0.44
MACD 0.32 -0.02
Stochastic Oscillator 15.75 83.82

Price Performance

Historical Comparison
NXGL
SHPH

About NXGL NexGel Inc

NexGel Inc manufactures high water content, electron beam cross-linked, aqueous polymer hydrogels, or gels, used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company specializes in custom gels by capitalizing on proprietary manufacturing technologies. The gels and consumer products are manufactured using proprietary and non-proprietary mixing, coating and cross-linking technologies.

About SHPH Shuttle Pharmaceuticals Holdings Inc.

Shuttle Pharmaceuticals Holdings Inc is a clinical-stage pharmaceutical company leveraging its proprietary technology to develop novel therapies designed to cure cancers. The company has one operating segment with a focus on the development of novel drug therapies, including cancer therapies, extending new applications of radiation therapy, and other drug development, including through the use of the Molecule.ai platform by the company as well as licensing the right to use Molecuile.ai to others. The company's goal is to extend the benefits of cancer treatments with surgery, radiation therapy, chemotherapy and immunotherapy. Radiation therapy (RT) is one of the effective modalities for treating cancers. Its pipeline includes: Ropidoxuridine, HDAC Inhibitors, PSMA-B, and PC-Rad Test.

Share on Social Networks: